| This week's sponsor is CMIC Group. | | | Considering Japanese Market Entry?
As Japan's largest CRO with end-to-end solution, CMIC Group is your most experienced partner in Japan & the US. Our experts will help you determine the best strategy at any stage of drug development.
Click here to learn more! |
Today's Rundown Compugen cuts 35% of workforce to push cash runway into mid-2020 Immunomedics could be facing longer lead drug delay as CEO quits Amicus plans to center its gene therapy R&D in Philadelphia with new lab [Sponsored] Rise in Targeted Therapies Drives Need for Flexible, Small-Volume Manufacturing Syncona, Novartis back IL-2 immuno-oncology startup Anaveon Purdue Pharma taps TetraGenetics for ion channel-focused pain treatments in $273M discovery pact Notable Labs brings on 2 development executives ahead of its first blood cancer trials Immatics, Roche ally to trial Tecentriq with cell therapy Featured Story | | | Tuesday, February 26, 2019 Compugen is “streamlining” its R&D operations to pare down costs and ensure it can afford the phase 1 study of its lead asset, an anti-PVRIG antibody it is developing for various cancers. |
|
|
| This week's sponsor is Sprout BioVentures. | | | Final Week for Golden Sprout Competition
Don’t miss out on 6 months of chemistry support at no cost. Strengthen your chemical starting points and work with a world-class research organization trusted by global biopharma. Click here to download the application. |
Top Stories Tuesday, February 26, 2019 Immunomedics CEO Michael Pehl is heading for the exit as analysts at Jefferies suggest the delay to IMMU-132 for breast cancer could be longer than first expected. Tuesday, February 26, 2019 Amicus Therapeutics plans to build a gene therapy R&D center in the heart of Philadelphia’s University City, not long after inking a $100 million deal to acquire Celenex and its 10 gene therapies. Monday, February 25, 2019 Biologics have experienced steady double-digit growth over the last 15 years and now comprise slightly more than a quarter of all New Molecular Entity (NME) FDA approvals. Tuesday, February 26, 2019 Syncona and Novartis have invested in Anaveon. The $35 million series A round sets Anaveon up to advance a preclinical asset designed to enhance anti-tumor immune responses. Tuesday, February 26, 2019 Purdue Pharma’s newly formed clinical research subsidiary, Imbrium Therapeutics, has tapped TetraGenetics and its antibody discovery platform to help it develop new, non-opioid-based biologics for treating chronic pain. Tuesday, February 26, 2019 After launching its first in-house R&D program last month, cancer drug-testing startup Notable Labs has brought on two biopharma executives to take charge of its clinical operations and drug development work. Tuesday, February 26, 2019 Immatics has struck a deal to test its autologous cell therapy in combination with Roche’s checkpoint inhibitor Tecentriq. The clinical collaboration clears Immatics to test whether Roche’s antibody boosts the efficacy of its IMA101 in solid tumors. Resources Sponsored by: Blue Matter White paper outlining the key types of cell-based immunotherapies in oncology, as well as the development and commercial outlook for each. Sponsored by: AlphaSense It’s never been more challenging to stay on top of trends and innovation shaping the future of healthcare. Discover how AI can help competitive intelligence teams achieve more proactive strategies. Sponsored by: Patheon, part of Thermo Fisher Scientific When a biologics company prepares to launch a new product, it must forecast the manufacturing capacity it will need, factoring in its estimate of the size of future sales, the timing of the launch, the dosage of the product, its strategy for building its market and a host of other variables. Sponsored by: Oracle Health Sciences 92% of survey respondents make changes to their RTSM/IRT systems due to study changes. See what else puts a strain on their clinical trials. Download the Research Whitepaper. Sponsored by: Patheon, part of Thermo Fisher Scientific Download this whitepaper to learn more. Sponsored by: The Kinetix Group Explore how the pharma industry can adapt its approach to the changing healthcare marketplace in the era of the Quadruple Aim Sponsored by: Cofactor Genomics Learn how Health Expression Models provide increased sensitivity, specificity, and accuracy for characterizing immune response in solid tumor specimens. Sponsored by: BioAnalytix, Inc. This whitepaper reviews fundamental aspects of HCPs that pertain to biologic drug development and presents current and emerging approaches to HCP analysis. Sponsored by: Veradigm Clinical trials take too long and cost too much—here's what needs to change. Sponsored by: Outer Edge Technology With FDA approval imminent, start-up Life Sciences company partners with an industry focused MSP to design and manage its regulated cloud-based infrastructure to speed time to market. Presented by: Veeva Share your thoughts on the life sciences industry's progress in improving study execution. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. BIO Asia International Conference March 5-6, 2019 | Grand Hyatt Tokyo | Tokyo, Japan BioBasics: Biotech For The Non-Scientist March 28-29, 2019 | Boston, MA Drug Development Immersion April 3-4, 2019 | Philadelphia, PA PEGS: The Essential Protein Engineering Summit April 8 – 12, 2019 | Boston, MA Middle East Life Sciences Compliance Training April 29, 2019 – May 2, 2019 | Dubai U.A.E. 2019 BIO International Convention June 3-6, 2019 | Philadelphia, PA Drug Development Boot Camp® 2019 November 20-21, 2019 | Boston, MA | Register and start preparing Today! | 